摘要
目的探讨芪苈强心胶囊治疗慢性心力衰竭(CHF)的临床效果,为提高CHF疗效提供参考。方法选择石河子大学医学院第一附属医院2015年2月—2017年2月收治的CHF患者80例,随机分为观察组和对照组,各40例。对照组采用常规内科治疗方法,观察组在对照组的基础上加用芪苈强心胶囊进行治疗。两组疗程均为8周。疗程结束后,观察两组疗效及两组不良反应发生情况,6 min步行试验(6MWT),采用酶联免疫法(ELISA)检测血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、高敏C反应蛋白(hs-CRP)及血浆脑钠肽(BNP)水平,超声心电图检查两组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)及左室射血分数(LVEF)水平。结果对照组总有效率(67.50%)低于观察组(90.00%),差异有统计学意义(P<0.05)。治疗前,两组TNF-α、IL-6、hs-CRP、BNP及6MWT水平比较,差异无统计学意义(P>0.05);治疗后,观察组TNF-α、IL-6、hs-CRP及BNP水平均低于对照组,6 MWT高于对照组,差异有统计学意义(P<0.05)。治疗前,两组LVEDD、LVESD及LVEF水平比较,差异无统计学意义(P>0.05);治疗后,观察组LVEDD及LVESD水平低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率为12.50%,与对照组的10.00%比较,差异无统计学意义(P>0.05)。结论在常规综合治疗的基础上联合应用芪苈强心胶囊治疗CHF可以取得显著的治疗效果,改善患者的心功能。
Objective To investigate the clinical effect of Qiliqiangxin capsule in treatment of chronic heart failure(CHF). Methods Totally 80 patients with CHF admitted from February 2015 to February 2017 were randomly divided into observation group(n=40) and control group(n=40). The control group was treated with conventional treatment for CHF. The observation group was treated with Qiliqiangxin capsule on the basis of the control group. Both groups were treated for 8 weeks. Before and after treatment, clinical effect, 6 minutes of walking test(6MWT) and adverse effect of both groups were observed and compared. The levels of tumor necrosis factor-alpha(TNF-α), interleukin-6(IL-6), high-sensitivity C-reactive protein(hs-CRP) and brain natriuretic peptide(BNP) were measured by enzyme-linked immunosorbent assay(ELISA). Results The total effective rate in the observation group was higher than that in the control group(90.00% vs. 67.50%, P<0.05). After treatment, IL-6, TNF-α, hs-CRP and BNP levels in the observation group were lower than those in the control group(all P<0.05). Compared with the control group, 6MWT in the observation was higher(P<0.05). After treatment, the levels of left ventricular end-diastolic dimension(LVEDD),left ventricular end-systolic dimension(LVESD) and left ventricular ejection fraction(LVEF) in the observation group were improved significantly(all P<0.05). During the treatment period, there was no significant difference of incidences of adverse reactions between the two groups(12.50% vs.10.00%,P>0.05). Conclusion Qiliqiangxin capsule combined with the routine treatment for CHF can achieve significant therapeutic effect and improve the patients' heart function.
出处
《慢性病学杂志》
2017年第8期864-867,共4页
Chronic Pathematology Journal
关键词
芪苈强心胶囊
慢性心力衰竭
心功能
Qiliqiangxin capsule
Chronic heart failure
Cardiac function
